ZeaVaxx
ZEAVAXX LLC is an Indiana-based animal healthcare company dedicated to improving current animal vaccines through a plant-derived nanoparticle adjuvant platform. Their proprietary platform, Zea-11, is a glucan-based nanoparticle derived from plants, designed to enhance vaccine efficacy. Founded by experts from Purdue University, the company aims to revolutionize veterinary vaccines with innovative technology.
Industries
Nr. of Employees
small (1-50)
ZeaVaxx
West Lafayette, Indiana, United States, North America
Products
Plant-derived glucan-based nanoparticle adjuvant
A glucan-based nanoparticle material extracted from plants and chemically functionalized for use as an adjuvant in animal vaccine formulations; positioned as a cost-feasible alternative to traditional aluminum-containing adjuvants.
Plant-derived glucan-based nanoparticle adjuvant
A glucan-based nanoparticle material extracted from plants and chemically functionalized for use as an adjuvant in animal vaccine formulations; positioned as a cost-feasible alternative to traditional aluminum-containing adjuvants.
Services
Licensing of nanoparticle adjuvant technology
Licensing the plant-derived nanoparticle adjuvant platform to animal healthcare and vaccine companies for integration into vaccine product lines.
Proprietary animal vaccine development
Development of proprietary animal vaccine candidates that incorporate the plant-derived nanoparticle adjuvant platform.
Licensing of nanoparticle adjuvant technology
Licensing the plant-derived nanoparticle adjuvant platform to animal healthcare and vaccine companies for integration into vaccine product lines.
Proprietary animal vaccine development
Development of proprietary animal vaccine candidates that incorporate the plant-derived nanoparticle adjuvant platform.
Expertise Areas
- Animal vaccine development
- Adjuvant development
- Nanoparticle formulation
- Vaccine formulation and compatibility
Key Technologies
- Plant-derived glucan nanoparticles
- Nanoparticle-based adjuvants
- Chemical functionalization of biomaterials
- Vaccine formulation methods